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ABSTRACT
Malaria  is  a  preventable  disease,  which  is  under  notified  in  the  UK. This  study  sought  to  evaluate  the  current 
surveillance arrangements in Northern Ireland (NI), describe the epidemiology of malaria and make appropriate 
recommendations.
A case was defined as a resident or visitor to NI with laboratory confirmed malaria, diagnosed by the NI haematology 
laboratories and/or the Malaria Reference Laboratory (MRL) from 1998-2003. Laboratory data were compared with 
notifications and hospital admission data.
One hundred and fourteen laboratory cases were identified compared with 63 notifications received by the regional 
surveillance centre. Six cases were associated with two episodes of malaria reflecting recurrence and or reinfection. P. 
falciparum was the most common infection with two fatalities reported; this was particularly associated with travel to 
West Africa. Most cases were associated with short visits to malarious areas. Thirty-three percent of all cases did not 
take prophylaxis and, of those that did, approximately half were taking a prophylactic regime appropriate to the region 
visited.
This study highlights the need for improved surveillance of malaria in order to capture risk factors and other relevant 
information to inform public and professional education. This would facilitate increasing local awareness, enhancing 
prescription of and compliance with appropriate chemoprophylaxis and enabling early diagnosis and treatment of 
malaria.
INTRODUCTION
Malaria is a disease that affects 40% of the world’s population, 
mainly  in  tropical  and  subtropical  countries.  The  World 
Health  Organisation  estimates  that  malaria  accounts  for 
more than 300 million acute illnesses and at least one million 
deaths annually.1 Human malaria is caused by Plasmodium 
falciparum, P . malariae, P . ovale and P . vivax.  P . falciparum 
has the highest fatality rate compared with the other three 
types of malaria infection.2 The number of imported cases of 
P . falciparum in the UK has risen steadily since the 1970s.3 
Challenges to the prevention and control of malaria include 
raising public awareness and compliance with appropriate 
chemoprophylaxis. A further challenge is the development of 
antimicrobial resistance to common anti-malarial drugs such 
as chloroquine which are used for prophylaxis.
Malaria is a statutory notifiable disease in Northern Ireland 
requiring the clinician to notify the patient to the Director of 
Public Health of the Health and Social Services Board. In 
practice, these notifications are received by the Consultant in 
Communicable Disease Control (CCDC). Notifications are 
based on clinical suspicion and laboratory confirmation is not 
required for the purposes of the legislation. However malaria 
notifications are frequently under-reported.4 
The  aims  of  this  study  were  (a)  to  evaluate  the  current 
malaria surveillance arrangements in NI; (b) to describe the 
epidemiology of imported malaria to NI between 1998-2003; 
and (c) to suggest appropriate recommendations to improve 
surveillance for better prevention and control of imported 
malaria.
METHODS
A case was defined as an individual who was a resident or 
visitor to Northern Ireland with malaria confirmed by the 
NI  haematology  laboratories  and/or  the  London  Malaria 
Reference Laboratory (MRL) from 1998-2003.
The  current  MRL  patient  report  form  was  used  for  data 
collection. The  data  was  entered  on  to  Epi  Info  version 
6.03 (Centres for Disease Control, Atlanta) and the analysis 
undertaken  at  the  Communicable  Disease  Surveillance 
Centre, Northern Ireland [CDSC (NI)].
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Data sources
Data was sought on age; gender; onset of illness; dates and 
reason for travel; countries visited; prophylaxis taken; method 
of diagnosis; species of parasite; and outcome of illness. 
Information on date of birth and gender was used to identify 
duplicate reports.
Data was obtained from the haematology laboratories, MRL, 
Regional Infectious Diseases Unit, CsCDC, Department of 
Health, Social Services and Public Safety (DHSSPS) Regional 
Information Branch, Registrar General and CDSC (NI).
RESULTS
Data Source
Requests  for  malaria  tests  originated  from  the  Regional 
Infectious Diseases Unit, acute medical wards and general 
practitioners  (GP).  There  were  1774  requests  (including 
repeats) for malaria tests (1998-2003) submitted to the main 
Belfast laboratory of which the majority (approximately 80%) 
were from hospital sources. Of the 114 positive cases, 99 were 
from the hospital (i.e. Regional Infectious Diseases Unit and 
acute medical wards).
Laboratory reports refer to malaria confirmed reports from 
the haematology laboratories and/or MRL. Fig. 1 illustrates 
the number of laboratory-confirmed malaria cases per annum 
and the annual number of falciparum cases from 1998-2003. 
One hundred and fourteen laboratory confirmed cases were 
identified which equate to an average incidence rate of 1.1 
per 100,000 population using the 2002 mid year estimate. 
These  114  cases  involved  108  individuals  as  six  patients 
had either a relapse and/or reinfection. Table I describes the 
proportion of laboratory confirmed malaria cases from each 
data source. There were 10 cases identified by the MRL with 
no corresponding haematology laboratory report.
Age, gender, ethnicity
The average age of patients was 33 years (age range 2-80, 
median 31 years, mode 22 years). The male to female ratio 
was 2:1 (78 males, 36 females). Ethnicity was available on 
104/114 patients of whom 94/104 (90%) were Caucasian. The 
other ethnic backgrounds 10/104 (9%) included Black African 
(7) and South-East Asian (3).
Travel history
Travel history was available on 110/114 (97%) patients. The 
most frequently visited region was Africa (98/110, 89%), 
with West Africa being the region with the greatest number 
of  associated  cases  (39/110,  36%).  South-East Asia  was 
visited by 8/110 (7%) of cases followed by India/Pakistan 
(4/110, 4%).
The reasons for travel were obtained from 52/114 (46%) 
cases (Table II) together with history of prophylaxis. The 
majority were short term travellers (29/52, 57%) comprising 
holiday makers or those on short mission trips (18/52, 35%) 
and business/professional travellers (11/52, 21%). Long term 
travellers (12/52, 24%) included expatriates living, studying 
and working abroad (including armed forces) and individuals 
visiting friends and relatives in their country of origin (4/52, 
8%).  In 1998 there was a cohort of nine patients infected with 
P . ovale following a church organised trip to Kenya. Seven 
cases (7/52, 14%) were visitors to NI including three members 
of an African children’s choir.
The length of stay in malarious regions was available on 
98/114 (86%) patients. The average duration was 7 months 
(206 days) but the most common period was two weeks (14 
days). The length of stay ranged from five days to eight years 
with a median of two months (60 days). However there were 
four patients (UK citizens living abroad) whose length of stay 
was unknown.
Plasmodium species
The  most  common  species  of  malaria  was  P .  falciparum 
(65/114, 57%), followed by P . vivax (21/114, 18%), P . ovale 
(20/114, 18%) and P . malariae (2/114, 2%). The plasmodium 
species was not identified in three cases. A combination of 
two plasmodium species (P . ovale and P . falciparum, P . vivax 
and P . falciparum, P . ovale and P . malariae) was noted in three 
patients. A church group was associated with nine reports of 
P . ovale (see earlier).
Table III describes the number of cases, classified by species, 
associated with travel history. There were 65 cases with P . 
falciparum infection all of whom had visited Africa. Thirty-
three (33/39, 85%) of those acquiring malaria in West Africa 
had infection with P . falciparum compared with 18 (18/37, 
49%) visiting East Africa. All those presenting with malaria 
and travel to the Indian sub-continent and South East Asia 
had P . vivax infection. The time interval for presentation of 
disease as calculated from date of arrival into the UK to date 
of laboratory diagnosis is given in Table IV .
Prophylaxis
Prophylaxis history was available on 103/114 (90%) cases 
of  which  65/103  (63%)  reporting  taking  prophylaxis  and 
38/103 (37%) did not. The number of travellers who sought 
travel advice was not recorded as part of the data collection. 
However  it  is  presumed  that  those  who  took  appropriate 
prophylaxis  probably  did  seek  travel  advice.  Thirty-four 
(34/65,  52%)  travellers  took  prophylaxis  appropriate  to 
the country they were visiting with 25/34 (74%) taking it 
regularly  while  abroad  but  only  13/34  (38%)  continued 
prophylaxis for four weeks on return from travel as advised 
under current guidelines.
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Fig 1.  Annual  number  of  laboratory-confirmed  malaria 
cases  and  those  of  P.  falciparum,  1998-2003, 
Northern Ireland.
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The type of prophylaxis taken and countries visited are shown 
in Table V .  Of the 62/98 (63%) travellers to Africa who took 
prophylaxis, 26 took mefloquine which is one of the drugs 
of choice in malarious regions with chloroquine resistance. 
Chloroquine was used in combination with proguanil by 17 
travellers to Africa and as a single agent by six cases. Five 
took doxycycline of which one took it in combination with 
chloroquine.
Twelve cases travelled to India/Pakistan, South-East Asia and/
or Papua New Guinea of whom three took chemoprophylaxis. 
Each of the three took chloroquine and proguanil, doxycycline 
and mefloquine as part of the recommended chemoprophylaxis 
regime.
Table II shows that twenty four (24/29, 83%) short term 
travellers  (previously  defined)  took  prophylaxis  of  which 
11/24 (46%) was consistent with current guidelines. Fourteen 
of the former (14/24, 58%) took prophylaxis regularly while 
abroad but only seven (7/24, 29%) continued the regimen 
for four weeks on return to NI. Eight (8/12, 67%) of the 
expatriates took prophylaxis of which 5/8 (63%) took the 
appropriate anti-malarial drug with four (4/8, 50%) taking it 
regularly while abroad but only one (1/8, 13%) completed the 
month’s course on return. The foreign visitors to NI did not 
take any prophylaxis and three of the four visiting friends and 
relatives in their country of origin did not take prophylaxis 
(Table II).
        Plasmodium species
  Total     
Year  cases  falciparum  vivax  ovale  malariae  unknown  combination
98  16  6  12  0  1  0  35
99  13  1  1  0  0  0  15
2000  9  4  2  0  0  0  15
2001  11  4  4  0  2  1  22
2002  11  2  0  1  0  1  15
2003  5  4  1  1  0  1  12
Total  65  21  20  2  3  3  114
(Accompanying table)
Table  I
Number and percentage of confirmed malaria cases by 
referring source, 1998 – 2003, Northern Ireland (n=114)
Data Source  No. reported (%)
NI haematology labs  104 (91.2)
MRL  33 (28.9)
CCDC  69 (60.5)
CDSC (NI) (notifications)  63 (55.3)
Regional information branch (RIB)  68 (59.6)
Regional Infectious Diseases Unit  80 (70.2)
Inpatient information
The 114 cases were associated with 99 hospital admissions. 
The inpatient length of stay was available on 88/99 (89%) 
cases. The mean length of stay was 4 days (range 1-20 days, 
mode and median of 3 days). Two patients required renal 
dialysis and three required ICU support. Among the 114 cases 
were two malaria related deaths (a case fatality rate of 1.8 
%). Both were associated with travel to Nigeria and infection 
with P . falciparum. One had not taken chemoprophylaxis and 
information on the other was missing.
Recurrence
Incomplete  treatment  or  drug  resistance  may  lead  to 
recurrence of malaria. Co-infection with P . vivax or P . ovale 
may result in these species lying dormant in a patient resulting 
in break-through infection if compliance to chemoprophylaxis 
is poor or inappropriate. Six (6/108, 6%) patients had two 
episodes of malaria. In this study each malaria episode was 
counted as one case. The average time interval between the 
two episodes was 14 months (range 3-46 months). Two had 
recurrence of falciparum malaria. The remaining four cases 
had combinations of falciparum malaria followed by infection 
with P . ovale (2), P . ovale followed by P . vivax (1) and P . 
falciparum and P . vivax followed by P . ovale (1).
DISCUSSION
This study demonstrated that statutory notifications of malaria 
were associated with an under-ascertainment rate of 45%. 
Possible reasons for under notifying include clinicians being 
unaware that malaria is a notifiable disease and the mechanism 
for informing the CCDC. It is not a statutory requirement 
for laboratories to notify all positive results to the CCDC or 
send laboratory reports to CDSC (NI). The annual incidence 
rate of imported malaria to Northern Ireland over this six 
year period (1.1/100,000) is much lower compared to other 
parts of the UK. This reflects the travel history and ethnicity 
of the Northern Ireland population, which is predominantly 
Caucasian. In a study in southeast London the incidence rate 
of malaria was 38.8 per 100,000 population, which accounted 
for 14% of all cases in England and Wales in 20004. In this 
London study only 6.8% of laboratory confirmed cases were 
formally notified.©  The Ulster Medical Society, 2006.
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Table  II
Reason for travel of malaria patients and prophylaxis history, 1998 – 2003, Northern Ireland (n=52)
Reason for travel  Frequency  Percentage %    Prophylaxis 
      Taken  Appropriate  Regularly  4 weeks
        to region  abroad  on return
Short term traveller  29  56.8  24  11  14  7
Expatriates  12  23.5  8  5  4  1
VFR  4  7.6  1  No history  –  –
Foreign visitors to NI  7  13.7  0  n/a  n/a  n/a
VFR= visiting friends and relatives in country of origin.
Table  III
Plasmodium species per patient by region of travel, 1998 – 2003, Northern Ireland
Region                Plasmodium            Total
  falciparum  vivax  ovale  malariae  unknown  combination
Africa             
Central  8  2  3  0  0  0  13
East  18  1  3  14  2  0  1  1 (fal +vivax)  37*
West  33  0  3  2  0  1 (falc+ovale)  39
South  6  3  0  0  0  0  9
            0 
South East Asia (SEA)  0  8  0  0  0  0  8*
            0 
India/Pakistan  0  4  0  0  0  0  4
            0 
Unknown  0  1  0  0  2  1 (oval+mal)  4
Total  65  21  20  2  3  3  114
* 1 patient in each of these regions also visited South America,1 One patient also travelled to South Africa,2 One patient also 
travelled to SEA.
Table  IV
Time of presentation (date of lab diagnosis-date of arrival in UK) to hospital/GP for malaria, 1998 – 2003,
Northern Ireland  (n = 76)
Plasmodium species  Time interval between arrival to UK and lab diagnosis (days)
  Range  Median  Mean
P. falciparum  (-2)*- 35  8  10
P. vivax  1-365  90  104
P.ovale  14-244  116  116
P.malariae  36-112  74  74
Combination of 2 species  12-20  16  16
Note: *One patient diagnosed 2 days prior to return to UK
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Malaria  is  a  relatively  uncommon  diagnosis  in  Northern 
Ireland. Nevertheless the 114 cases reported between 1998 and 
2003 contrast with 18 cases of Legionnaires’ disease reported 
over the same period (CDSC (NI) – personal communication). 
With  the  growth  in  air  travel,  more  independent  travel, 
increased immigration and an increasing tendency to buy 
“last minute” breaks, there is likely to be more travel between 
Northern Ireland and malarious regions. A recent example is 
the increased number of patients returning to the UK from 
Gambia and developing malaria.5 Travellers need therefore to 
be reminded of appropriate precautions and the importance 
of alerting their general practitioners to their travel history 
should they develop fever on return from a malarious region. 
Falciparum malaria usually presents early within two weeks of 
being bitten but can present up to 90 days later whereas ovale 
and vivax malaria has been reported to present from 20 days 
to 10 months on return.6 Collation of risk factor information 
on imported malaria enables the development of targeted 
public and professional awareness programmes for this mainly 
preventable and curable infection.
Risk factor information on cases was incomplete particularly 
with respect to reasons for travel (55%) and chemoprophylaxis 
(12% either missing or unspecified). To ensure that relevant 
risk factors and epidemiological information are obtained it 
is suggested the MRL case questionnaire be routinely used 
by  CsCDC  when  responding  to  a  clinical  notification  of 
Table  V
Countries visited and prophylaxis history (n=114)
Drug     Africa      South Asia        Total
  Central  East  West  South  India  Pakistan  SEA/  Un-
                Oceania  known
NONE TAKEN  5  8  16  1  1  2  5  0  38
  SEA(1)  SAM(1)    WA(1)      SAM(1)
  WA(1)
Mefloquine  3  13  8  2  0  0  1  0  27
  EA(1)
Chloroquine  2  10  3  2  0  0  1  0  18
+Proguanil  SA(1)  SA(1)    EA(1) 
No history  2  1  3  0  1  0  0  4  11
available  SA(1) 
Chloroquine  0  3  2  1  0  0  0  0  6
     SEA(1)
Doxycycline  0  0  3  1  0  0  1  0  5
Medication unspecified  0  1  2  0  0  0  0  0  3
       SEA(1) 
Proguanil  1  0  0  2  0  0  0  0  3
  SA (1)      EA(1)
Proguanil+  mefloquine  0  0  1  0  0  0  0  0  1
Chloroquine +Doxycycline  0  0  1  0  0  0  0  0  1
Fansidar  0  1  0  0  0  0  0  0  1
Total  13  37  39  9  2  2  8  4  114
The letters in superscript indicate the number of travellers that travelled to other places as well. EA= East Africa, WA= West Africa, SA=South 
Africa, SEA= South east Asia, SAM= South America
malaria. To improve ascertainment it is also recommended 
that  haematology  laboratories  report  positive  blood  films 
to CsCDC similar to the reporting arrangements developed 
with bacteriology laboratories for organisms of public health 
significance. Clinicians also need to be reminded that malaria 
is a notifiable disease.
Noting  the  changing  epidemiology  of  malaria  and  drug 
resistance, clinicians also require access to updated guidance 
on  chemoprophylaxis  and  treatment.  There  are  several 
helpful telephone contact numbers and websites listed in the 
British National Formulary for healthcare professionals and 
travellers. These include the Health Protection Agency, the 
National Travel Health Network and Centre, Health Protection 
Scotland and the World Health Organisation. Travellers could 
also contact the London Hospital of Tropical Diseases or 
MASTA (Minding your Health Abroad) for a travel brief 
which incurs a charge. These and other sources of travel health 
advice should be promoted at GP surgeries and high street 
travel agents in order to raise awareness among intending 
travellers to malarious areas. Those taking trips abroad at 
short notice may not have time to consider taking preventative 
treatment or let appropriate therapeutic drug levels develop 
before travel. Hence the risk needs to be highlighted at the 
planning stage by the travel industry. A previous study showed 
25% of travel brochures contained no health information at 
all.7 Another study showed that spontaneous health warnings ©  The Ulster Medical Society, 2006.
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Table  VI
Comparison of malaria species between studies 1998-2003 Northern Ireland, 1974-1983 Northern Ireland and HPA report 2004
  Reports                    Plasmodium species
    P . falciparum  P . vivax
  NI 1974-198310  40% (27/67)  3% (2/67)
  NI 1998-2003  56% (65/114)  18% (21/114)
  HPA UK report  9 1987  38% (696/1816)  55% (1005/1816)
  HPA UK report  9 2002  76% (1468/1944)  15% (284/1944)
were not given in 61% (123) of consultations for malarious 
destinations and, after prompting, only 37% of agents brought 
up the need for malaria prophylaxis for the journey.8 This 
apparent low level of verbal and written advice needs to 
be addressed by local initiatives and collaboration between 
public health practitioners and the travel industry.
The epidemiology of imported malaria in Northern Ireland 
is interesting as it differs from the rest of GB particularly in 
the ethnicity of cases and reasons for travel. The majority 
of patients in this study were Caucasians in contrast to GB 
where the majority were non Caucasian with 50% of all cases 
visiting friends or relatives.9 In Northern Ireland the majority 
were  holiday  makers  and  those  on  business/professional 
travel, noting that travel history was only available on 45% 
of cases. Differences were also noted when compared to an 
earlier study of 67 imported cases of malaria to Northern 
Ireland between 1974 and 1983 in which the majority of 
cases  were  long  term  residents  working  overseas  (14/67, 
21%) whereas short term travellers (29/52, 57%) made up the 
majority in 1998-2003.10
There are over 2000 cases of imported malaria annually in 
the UK of which the majority are secondary to P . falciparum. 
The predominant species in the UK has changed over the past 
15 years from P . vivax to P . falciparum.  In 1987 cases were 
mainly from the Indian Subcontinent secondary to P . vivax 
infection whereas in 2002 the majority of UK cases were 
from West Africa with P . falciparum.9 However in NI the 
predominant species has not changed over the past 15 years.10 
In the UK (1987-2002) P. falciparum rates have increased by 
38% and P . vivax decreased by 40%, whereas in NI the rates 
of both these species have increased by 15% after 15 years 
(Table VI).
The average number of malaria deaths from 1977 to 2002 
in  the  UK  was  8  per  year  (a  case  fatality  rate  of  0.4% 
for  imported  malaria  and  1.0%  for  falciparum  cases).  In 
Northern Ireland there were two deaths in six years resulting 
in an overall case fatality rate (CFR) of 1.8%. The CFR for 
falciparum was nearly twice as high at 3.1%.
P . vivax and P . ovale have persistent liver stages and can give 
rise to relapses up to a year after the initial infection whereas 
P .  falciparum  rarely  persists  for  more  than  two  years.  P . 
malariae may persist in the bloodstream for many years. The 
time interval between arrival in the UK from a malarious 
region and the date of laboratory diagnosis confirms that 
patients with P . falciparum tend to present early whereas 
those with P . vivax and P . ovale infection tend to present late. 
Four patients had two episodes of malaria with two different 
species. This would suggest breakthrough infection with a 
species in the dormant phase resulting from co-infection or 
not complying with the prophylaxis regime and acquiring 
repeated malarial infections from visiting malarious regions. 
These cases also illustrate that the physician needs to be aware 
that a patient treated for one malaria parasite may be infected 
with another parasite that may be lying dormant.
The  current  guidelines  (2003)  recommend  four  steps  to 
prevent malaria in travellers:11 (a) awareness of the risk of 
malaria; (b) preventing and avoiding mosquito bites by using 
appropriate insecticides, repellents, sleeping in a screened 
room and using bed nets; (c) compliance with appropriate 
chemoprophylaxis and (d) diagnosing breakthrough malaria 
swiftly and obtaining prompt treatment. A useful publication 
on malaria prophylaxis for long –term travellers was also 
published in the same year.12 
Under current guidelines, mefloquine is the drug of choice 
for  travel  to  Africa  and  chloroquine  plus  proguanil  for 
South Asia  (Indian  subcontinent)  and  low  risk  places  in 
South  East  Asia  (Indonesia  /Malaysia)  or  mefloquine, 
doxycycline  or  atovaquone/proguanil  in  Oceania  (Papua 
New  Guinea).11  In  this  study  mefloquine  was  the  most 
common form of prophylaxis and mainly used for travellers 
to Africa. Nevertheless a third of cases did not take any form 
of chemoprophylaxis. Chloroquine and proguanil was the 
second most common chemoprophylactic drug regime. Over 
a third of travellers to Africa took chloroquine as prophylaxis 
despite chloroquine resistance being a major problem with P . 
falciparum. Travellers to the Indian subcontinent, South-East 
Asia and Oceania who took prophylaxis took the appropriate 
drug combination.
RECOMMENDATIONS
The following are recommended:
–  increase awareness among clinicians that malaria is a 
notifiable disease through multidisciplinary educational 
meetings.
–  haematology  laboratories  to  report  positive  results 
to CsCDC for public health purposes as part of good 
laboratory practice
–  enhanced surveillance (using a standard proforma such 
as the MRL case report form) to be used by CsCDC 
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to collect appropriate epidemiological and risk factor 
information which is essential for targeted public and 
professional education.
–  CDSC  (NI)  should  produce  regular  epidemiological 
reports  to  inform  public  and  professional  education 
including the travel industry.
–  GPs and travel agents require information on accessing 
appropriate travel health advice.
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Correction:
In the article by Lappin et al (Hox genes: seductive science, Mysterious mechanisms. Ulster Med J 
2006; 75(1): 23-31) there are two small corrections:
Page 23; Abstract: line 3– ‘... at 7p15, 17p21,’ should read ‘... at 7p15, 17q21’
Page 26; Hox GENES IN VERTEBRATES, Line 5 ‘... at 7p15, 17p21, 12q13’ should read ‘... at 7p15, 
17q21, 12q 13’
This was amended on the website PDF online on 7th February 2006 and the correct PDF may be 
downloaded free from the website.
Patrick Morrison, Honorary Editor.